The overexpression of PSMA in prostate cancer has been well documented, which has been widely applied, as a molecular target, in the clinical diagnosis and treatment of prostate cancer and exhibited extremely high sensitivity and performance. This evidence concerns the gene FOLH1 and prostate cancer.